New real-world evidence from ASH 2025: How anti-BCMA therapies are sequenced in relapsed/refractory multiple myeloma
During the Amercain Society of Hematology (ASH) meeting and exposition 2025, a major international congress in hematology, APLUSA presented a new real-world evidence poster on relapsed/refractory multiple myeloma. As BCMA-targeted options rapidly expand, clinicians face a practical challenge in daily care: how to sequence CAR-T cells and bispecific antibodies in the absence of head-to-head trials.